12th Feb:Efficacy of AC102 for the Preservation of Residual Hearing following Cochlear Implantation Dr. Michael Nieratschker from Allgemeines Krankenhaus Medical University of Vienna, Austria will present preclinical results performed in a model of electrode insertion...
At the start of the Phase II clinical trial, AudioCure Pharma GmbH will provide their newest insights on the mode of action of lead candidate AC102 at the 2nd Summit in Boston from 20-23 June 2022. AC102 is AudioCure’s clinical Phase I tested lead candidate for...
The FDA has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may become of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL). Comprehensive...
Berlin, 3 March 2021 – The 3rd of March is World Hearing Day. On the occasion the World Health Organization (WHO) issued its first World Report on Hearing. Hearing disorders are known to be a global problem. The WHO however warns that by 2050 nearly 2.5 billion people...
Phase I trial to assess safety, tolerability and pharmacokinetics of AC102-suspension after application into the middle ear of healthy volunteers Milestone achievement for AudioCure Pharma on its way to combating hearing loss disorders with unmet medical need Berlin,...
AudioCure has made exciting progress in its preclinical program by extending both its indication and compound pipelines in recent months. We are very pleased to announce that we have therefore extended our scientific team to continue pushing our preclinical...
